In eMSC-treated mice, primary tumor CD8α+ T-cell percentages significantly increased, but, similarly to total CD3ε+ T-cell percentages, CD4+ T-cell depletion did not affect this increase (Figure 5F). This evidence concerns the gene CD3E and neoplasm.